WALTHAM, Mass., July 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report second quarter 2008 results on Monday, August 4, 2008. A conference call and webcast hosted by OXiGENE management will begin at 2:00 p.m. EDT (11:00 a.m. PDT).
To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investor Center" tab, select the link to "Presentations & Conference Calls."
OXiGENE's earnings conference call can also be heard live by dialing (888) 208-1507 in the United States and Canada, and (913) 312-0402 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 5:00 p.m., EDT (2:00 p.m., PDT) on August 4, 2008 and ending at 5:00 p.m. EDT (2:00 p.m., PDT) on Monday, August 11, 2008. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 6113741.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4969